Investigational drug · Phase 3
I004
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pharmacokinetics, Pharmacodynamics, Insulin Aspart.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "I004"
First trial start
2026
Apr 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "I004", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pharmacokinetics
- Pharmacodynamics
- Insulin Aspart
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "I004" as an intervention, largest first.
Amphastar Pharmaceuticals, Inc.Industry
NCT05539872 · 69 participants · Start Aug 22, 2022 · Primary completion Jan 29, 2023
Drug: I004; NovoLog · For: Pharmacokinetics; Pharmacodynamics
Sites: Chula Vista, California
Amphastar Pharmaceuticals, Inc.Industry
NCT07560150 · 62 participants · Start Apr 6, 2026 · Primary completion Jun 22, 2026
Drug: I004; NovoLog · For: Pharmacokinetics; Pharmacodynamics; Insulin Aspart
Sites: Chula Vista, California
Newest research
PubMed records naming it or its code names, newest first.
- Eight-amino-acid sequence at the N-terminus of SARS-CoV-2 nsp1 is involved in stabilizing viral genome replication.
Ueno S, Amarbayasgalan S, Sugiura Y, et al. · Virology 2024
Also in development for Pharmacokinetics
- IPG7236Phase 22 trials
Nanjing Immunophage Biotech Co., Ltd · Advanced Solid Tumor, Safety Issues, Tolerability
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.